These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 8389668)
1. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. Rege SD; Hoh CK; Glaspy JA; Aberle DR; Dahlbom M; Razavi MK; Phelps ME; Hawkins RA Cancer; 1993 Jul; 72(1):82-90. PubMed ID: 8389668 [TBL] [Abstract][Full Text] [Related]
2. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer? Aquino SL; Fischman AJ Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753 [TBL] [Abstract][Full Text] [Related]
3. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Sazon DA; Santiago SM; Soo Hoo GW; Khonsary A; Brown C; Mandelkern M; Blahd W; Williams AJ Am J Respir Crit Care Med; 1996 Jan; 153(1):417-21. PubMed ID: 8542152 [TBL] [Abstract][Full Text] [Related]
4. Staging of recurrent and advanced lung cancer with 18F-FDG PET in a coincidence technique (hybrid PET). Schmid RA; Hautmann H; Poellinger B; Kellner W; Moisseev A; Brinkbaeumer K; Weiss M; Hahn K; Dresel S Nucl Med Commun; 2003 Jan; 24(1):37-45. PubMed ID: 12501018 [TBL] [Abstract][Full Text] [Related]
6. A comparative study of 11C-choline PET and [18F]fluorodeoxyglucose PET in the evaluation of lung cancer. Khan N; Oriuchi N; Zhang H; Higuchi T; Tian M; Inoue T; Sato N; Endo K Nucl Med Commun; 2003 Apr; 24(4):359-66. PubMed ID: 12673163 [TBL] [Abstract][Full Text] [Related]
7. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose. Hoh CK; Hawkins RA; Glaspy JA; Dahlbom M; Tse NY; Hoffman EJ; Schiepers C; Choi Y; Rege S; Nitzsche E J Comput Assist Tomogr; 1993; 17(4):582-9. PubMed ID: 8331230 [TBL] [Abstract][Full Text] [Related]
8. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Frank A; Lefkowitz D; Jaeger S; Gobar L; Sunderland J; Gupta N; Scott W; Mailliard J; Lynch H; Bishop J Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1495-512. PubMed ID: 7635795 [TBL] [Abstract][Full Text] [Related]
9. Whole-body [18F]FDG PET in the management of metastatic brain tumours. Kim DG; Kim CY; Paek SH; Lee DS; Chung JK; Jung HW; Cho BK Acta Neurochir (Wien); 1998; 140(7):665-73; discussion 673-4. PubMed ID: 9781280 [TBL] [Abstract][Full Text] [Related]
10. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. Hoh CK; Glaspy J; Rosen P; Dahlbom M; Lee SJ; Kunkel L; Hawkin RA; Maddahi J; Phelps ME J Nucl Med; 1997 Mar; 38(3):343-8. PubMed ID: 9074514 [TBL] [Abstract][Full Text] [Related]
11. Clinical significance of intrathoracic lesions detected by 18F-fluorodeoxyglucose positron emission tomography in the management of patients with head and neck cancer. Roh JL; Ryu CH; Kim JS; Lee JS; Choi SH; Nam SY; Kim SY Oral Oncol; 2007 Sep; 43(8):757-63. PubMed ID: 17112773 [TBL] [Abstract][Full Text] [Related]
12. Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET). Guhlmann A; Storck M; Kotzerke J; Moog F; Sunder-Plassmann L; Reske SN Thorax; 1997 May; 52(5):438-41. PubMed ID: 9176535 [TBL] [Abstract][Full Text] [Related]
13. Comparison of FDG-PET findings of brain metastasis from non-small-cell lung cancer and small-cell lung cancer. Lee HY; Chung JK; Jeong JM; Lee DS; Kim DG; Jung HW; Lee MC Ann Nucl Med; 2008 May; 22(4):281-6. PubMed ID: 18535878 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. Dewan NA; Gupta NC; Redepenning LS; Phalen JJ; Frick MP Chest; 1993 Oct; 104(4):997-1002. PubMed ID: 8404239 [TBL] [Abstract][Full Text] [Related]
16. [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions? Halter G; Buck AK; Schirrmeister H; Wurziger I; Liewald F; Glatting G; Neumaier B; Sunder-Plassmann L; Reske SN; Hetzel M J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1093-9. PubMed ID: 15052207 [TBL] [Abstract][Full Text] [Related]
17. Controlled prospective study of positron emission tomography using the glucose analogue [18f]fluorodeoxyglucose in the evaluation of pulmonary nodules. Präuer HW; Weber WA; Römer W; Treumann T; Ziegler SI; Schwaiger M Br J Surg; 1998 Nov; 85(11):1506-11. PubMed ID: 9823912 [TBL] [Abstract][Full Text] [Related]
18. Thoracic FDG PET: state of the art. Erasmus JJ; McAdams HP; Patz EF; Goodman PC; Coleman RE Radiographics; 1998; 18(1):5-20. PubMed ID: 9460106 [TBL] [Abstract][Full Text] [Related]
19. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose. Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554 [TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients. Wu Y; Li P; Zhang H; Shi Y; Wu H; Zhang J; Qian Y; Li C; Yang J Int J Cancer; 2013 Jan; 132(2):E37-47. PubMed ID: 22890912 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]